With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1317-39-1,Copper(I) oxide,as a common compound, the synthetic route is as follows.
3-Chloro-4-nitro-benzonitrile Sodium nitrite (6.78 g in water (40 mL) at 0 C.) was slowly added to a solution of 4-amino-3-chloro-benzonitrile (10.5 g) in water (30 mL) and concentrated hydrochloric acid (30 mL) also at 0 C. After 10 minutes the solution was poured onto a suspension of cuprous oxide (3.48 g) and sodium nitrite (31.69 g) in water (100 mL) at 0 C. The ensuing mixture was stirred at 0 C. for 1 hour then at 23 C. for 1 hour. The resulting mixture was extracted with dichloromethane and the organic layer washed with saturated sodium chloride. The separated organic layer was dried over sodium sulfate and then concentrated to give 3-chloro-4-nitro-benzonitrile (11.31 g).
1317-39-1, 1317-39-1 Copper(I) oxide 10313194, acopper-catalyst compound, is more and more widely used in various fields.
Reference£º
Patent; Pfizer Inc.; US2003/78432; (2003); A1;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”